Pradeep Ghimire
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pradeep Ghimire has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Aastha Parajuli
Kathmandu University Hospital, Kavrepalanchowk, Nepal
1 shared publication - Anil Pokhrel
Lecturer, Department of Nephrology, Kathmandu Medical College Teaching Hospital, Sinamangal, Kathmandu, Nepal
1 shared publication - Dipesh Upreti
Internal Medicine, St. Francis Medical Center, Monroe, Louisiana, United States
1 shared publication - Gajendra Bham
Badegaun Primary Health Care Center, Lalitpur, Nepal
1 shared publication - Hema Chand
Registrar, Department of Nephrology, Kathmandu Medical College Teaching Hospital, Sinamangal, Kathmandu, Nepal
1 shared publication - Laxman Prasad Adhikary
Professor, Department of Nephrology, Kathmandu Medical College Teaching Hospital, Sinamangal, Kathmandu, Nepal
1 shared publication
Latest Publications
- Open Access
- 22 May 2023
- Published by Nepal Journals Online (JOL) in Journal of Patan Academy of Health Sciences
- Vol. 10 (1) , 68-71
Lithium toxicity: a case report
Lithium is a commonly used drug for bipolar disorders and requires therapeutic dose monitoring due to its narrow therapeutic index. Acute lithium toxicity frequently occurs due to intentional intake of an excessive amount or due to its interaction with various medicines and medical conditions which alter its absorption or excretion. It may present primarily with neurological and gastrointestinal symptoms. We report a case of lithium toxicity in a patient with bipolar disorder probably due to dehydration and decreased intake of food and fluids. Frequent monitoring of serum lithium level while maintaining hydration and electrolyte balance successfully treated the lithium toxicity.
- 22 May 2023
- Published by Nepal Journals Online (JOL) in Journal of Patan Academy of Health Sciences
- Vol. 10 (1) , 68-71
Open AccessLithium toxicity: a case report
Lithium is a commonly used drug for bipolar disorders and requires therapeutic dose monitoring due to its narrow therapeutic index. Acute lithium toxicity frequently occurs due to intentional intake of an excessive amount or due to its interaction with various medicines and medical conditions which alter its absorption or excretion. It may present primarily with neurological and gastrointestinal symptoms. We report a case of lithium toxicity in a patient with bipolar disorder probably due to dehydration and decreased intake of food and fluids. Frequent monitoring of serum lithium level while maintaining hydration and electrolyte balance successfully treated the lithium toxicity.
- Open Access
- 1 March 2023
- Published by Nepal Journals Online (JOL) in Journal of Kathmandu Medical College
- Vol. 12 (1) , 10-16
Effectiveness of iron-based phosphate binders in reduction of hyperphosphataemia in chronic kidney disease patients
Background: Ferric citrate is novel iron-based phosphate-binding drug for management of hyperphosphataemia and iron-deficiency anaemia in chronic kidney disease (CKD) patients. Objectives: To evaluate impact of ferric citrate therapy on reduction of phosphate levels and improvement in haematological parameters in CKD stages 3-5. Methods: This analytical, observational study was conducted at Kathmandu Medical College Teaching Hospital from 2020 July-December after ethical clearance using convenience sampling method. Non-dialysis dependent patients at CKD stages 3-5, having hyperphosphataemia (serum phosphate >=4.6mg/dL) and anaemia (serum haemoglobin <12 gm%, transferrin saturation <=30%, ferritin <=300ng/mL) were administered with 2gm twice daily dose of ferric citrate for 12 weeks and evaluated on outcomes in terms of reduction in serum phosphate levels and improvement in haematological parameters as study endpoints. Data were entered in Microsoft Excel and analysed in SPSS v.25. Significance level was set at p <0.05. Results: Of 84 study participants, majority had CKD stage 4 (46, 54.76%). A significant reduction (p <0.001) in mean serum phosphate levels of 6.21 ± 1.062 mg/dL from baseline to 4.89 ± 1.100 mg/dL in 12-weeks was observed. Patients with CKD stages 3, 4, and 5 had mean reduction of 1.67 (p = 0.005), 1.40 (p <0.001), and 1.04 mg/dL (p = 0.002) of serum Phosphate level respectively. Significant (p <0.001) improvements in hemoglobin level, serum iron, ferritin, total iron binding capacity, and transferrin saturation were reported. Conclusion: Ferric citrate is effective and well-tolerated phosphate-binder to improve hyperphosphataemia and iron deficiency anaemia in non-dialysis CKD stage 3, 4, and 5.
- 1 March 2023
- Published by Nepal Journals Online (JOL) in Journal of Kathmandu Medical College
- Vol. 12 (1) , 10-16
Open AccessEffectiveness of iron-based phosphate binders in reduction of hyperphosphataemia in chronic kidney disease patients
Background: Ferric citrate is novel iron-based phosphate-binding drug for management of hyperphosphataemia and iron-deficiency anaemia in chronic kidney disease (CKD) patients. Objectives: To evaluate impact of ferric citrate therapy on reduction of phosphate levels and improvement in haematological parameters in CKD stages 3-5. Methods: This analytical, observational study was conducted at Kathmandu Medical College Teaching Hospital from 2020 July-December after ethical clearance using convenience sampling method. Non-dialysis dependent patients at CKD stages 3-5, having hyperphosphataemia (serum phosphate >=4.6mg/dL) and anaemia (serum haemoglobin <12 gm%, transferrin saturation <=30%, ferritin <=300ng/mL) were administered with 2gm twice daily dose of ferric citrate for 12 weeks and evaluated on outcomes in terms of reduction in serum phosphate levels and improvement in haematological parameters as study endpoints. Data were entered in Microsoft Excel and analysed in SPSS v.25. Significance level was set at p <0.05. Results: Of 84 study participants, majority had CKD stage 4 (46, 54.76%). A significant reduction (p <0.001) in mean serum phosphate levels of 6.21 ± 1.062 mg/dL from baseline to 4.89 ± 1.100 mg/dL in 12-weeks was observed. Patients with CKD stages 3, 4, and 5 had mean reduction of 1.67 (p = 0.005), 1.40 (p <0.001), and 1.04 mg/dL (p = 0.002) of serum Phosphate level respectively. Significant (p <0.001) improvements in hemoglobin level, serum iron, ferritin, total iron binding capacity, and transferrin saturation were reported. Conclusion: Ferric citrate is effective and well-tolerated phosphate-binder to improve hyperphosphataemia and iron deficiency anaemia in non-dialysis CKD stage 3, 4, and 5.